Spotlight on Dermatology

Credits: 0.25 CME / MOC
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases
Peter A. Lio, MD, FAAD
Global Education Group

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Start

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Dermatology Presentations

1.00 CME / CE
Vindico
Recent Advances in the Management of Psoriasis

Recent Advances in the Management of Psoriasis

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit(s)
AANP Contact Hours
AAPA Category 1 CME credit
Released: December 31, 2020
Expires: December 30, 2021
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Review the pathophysiology and comorbidities associated with psoriasis.
  • Apply current guideline-directed recommendations to the management of patients with psoriasis.
  • Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
  • Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.

Activity Description

Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.

Activity Co-Chairs

Mark Lebwohl, MD
Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB


Linda F. Stein Gold, MD
Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI

Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124656. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201757.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.

MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit(s)
AANP Contact Hours
AAPA Category 1 CME credit
Released: December 31, 2020
Expires: December 30, 2021
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Review the pathophysiology and comorbidities associated with psoriasis.
  • Apply current guideline-directed recommendations to the management of patients with psoriasis.
  • Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
  • Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.

Activity Description

Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.

Activity Co-Chairs

Mark Lebwohl, MD
Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB


Linda F. Stein Gold, MD
Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI

Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124656. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201757.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.

MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

1.25 CME
Vindico
Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Start

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 8, 2020
Expires: December 7, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
  • Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
  • Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
  • Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
  • Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.

Activity Description

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.

Agenda

Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO

Immunopathogenesis of SLE: Implications for Disease Manifestations and Treatment
Daniel J. Wallace, MD, FACP, MACR

Advances in the Treatment of SLE
Richard A. Furie, MD
 
Clinical Cases
Moderated by Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Faculty

Richard A. Furie, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY

Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA

Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 8, 2020
Expires: December 7, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
  • Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
  • Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
  • Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
  • Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.

Activity Description

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.

Agenda

Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO

Immunopathogenesis of SLE: Implications for Disease Manifestations and Treatment
Daniel J. Wallace, MD, FACP, MACR

Advances in the Treatment of SLE
Richard A. Furie, MD
 
Clinical Cases
Moderated by Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Faculty

Richard A. Furie, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY

Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA

Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Start

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME
Vindico
Chronic Idiopathic Urticaria Curbside Consults ̶ Impact of Guidelines on Patient Outcomes in Chronic Idiopathic Urticaria: A Closer Look

Chronic Idiopathic Urticaria Curbside Consults ̶ Impact of Guidelines on Patient Outcomes in Chronic Idiopathic Urticaria: A Closer Look

Start

Chronic Idiopathic Urticaria Curbside Consults—Impact of Guidelines on Patient Outcomes in Chronic Idiopathic Urticaria: A Closer Look

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the strengths and limitations of current guideline approaches to the management of chronic idiopathic urticaria (CIU).

Activity Description

Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Lang compare existing guidelines for treating urticaria, providing guidance on the application of guidelines recommendations to optimize diagnosis and management of CIU/CSU. 

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda

Faculty

David M. Lang, MD
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Chronic Idiopathic Urticaria Curbside Consults—Impact of Guidelines on Patient Outcomes in Chronic Idiopathic Urticaria: A Closer Look

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the strengths and limitations of current guideline approaches to the management of chronic idiopathic urticaria (CIU).

Activity Description

Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Bernstein and Lang compare existing guidelines for treating urticaria, providing guidance on the application of guidelines recommendations to optimize diagnosis and management of CIU/CSU. 

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda

Faculty

David M. Lang, MD
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Immune-Mediated Inflammatory Disease Curbside Consults: Psoriasis – New and Emerging Options for Disease Management

Immune-Mediated Inflammatory Disease Curbside Consults: Psoriasis – New and Emerging Options for Disease Management

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to select treatment for patients with psoriasis based on the latest clinical evidence and recommendations.

Activity Description

In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Actellion, Mallinkrodt, Novartis, UCB
Speakers Bureau: AbbVie, Mallinkrodt, Novartis
Contracted Research: Mallinkrodt, Novartis
Research Support for Clinical Trials: Corbus, Pfizer


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to select treatment for patients with psoriasis based on the latest clinical evidence and recommendations.

Activity Description

In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Actellion, Mallinkrodt, Novartis, UCB
Speakers Bureau: AbbVie, Mallinkrodt, Novartis
Contracted Research: Mallinkrodt, Novartis
Research Support for Clinical Trials: Corbus, Pfizer


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Pages